Qol Holdings (3034) Q4 2025 earnings summary

Executive summary

• Achieved record high consolidated sales and operating profit for the fiscal year ended March 2025, driven by segment expansion, M&A activity, and the consolidation of DAIICHI SANKYO ESPHA CO., LTD.

• EBITDA surged 60.9% to ¥21,827 million, reflecting strong underlying business performance.

• Major segment reclassification: now reporting Pharmacy Business, BPO Contracting Businesses, and Pharmaceutical Manufacturing Business.

• DAIICHI SANKYO ESPHA became a consolidated subsidiary, significantly impacting segment results and profit allocation; shareholding increased to 51% in April 2024, with plans to reach 80% in April 2025.

• Acquisition of additional 29% stake in DAIICHI SANKYO ESPHA CO., LTD. in April 2025, increasing total shareholding to 80%.

Financial highlights

• Net sales rose 46.6% year-over-year to ¥263,972 million; operating profit increased 61.8% to ¥13,465 million.

• Ordinary profit grew 49.4% to ¥13,831 million; profit attributable to owners of parent up 5.8% to ¥5,164 million.

• Gross profit increased to ¥39,056 million from ¥23,249 million year-over-year; gross profit margin improved to 14.8% from 12.9%.

• Basic earnings per share (EPS) increased to ¥137.97 from ¥131.11.

• Cash and cash equivalents at year-end were ¥26,378 million, down slightly from the previous year.

Outlook and guidance

• FY2025/2026 consolidated targets: net sales ¥280,000 million, operating profit ¥15,500 million, profit attributable to owners of parent ¥7,000 million.

• Segment targets: Pharmacy Business net sales ¥177,200 million, BPO ¥17,400 million, Pharmaceutical Manufacturing ¥87,300 million.

• Medium-term targets: net sales of ¥300 billion and operating profit of ¥24 billion.

• Dividend forecast increased to ¥46 per share for FY2025/2026, reflecting anticipated business expansion.